More stories

  • in

    Have Covid? You can’t get unemployment benefits

    There were more than 1 million new U.S. Covid-19 cases on Monday, a single-day record, according to Johns Hopkins University data.
    Americans who get Covid and miss work aren’t eligible for unemployment benefits. That wasn’t the case earlier in the pandemic due to the Pandemic Unemployment Assistance program.
    However, the same may not be true for people exposed (but not infected with) the virus.

    A healthcare worker administers a Covid-19 swab test at the Boulder County Fairgrounds testing site in Longmont, Colorado, on Dec. 14, 2021.
    Chet Strange/Bloomberg via Getty Images

    Covid-19 infections are ballooning, and sick Americans who miss work due to the virus may wonder if they qualify for unemployment benefits.
    The short answer: They don’t.

    There were more than 1 million new U.S. Covid cases reported Monday, a single-day record, according to data compiled by Johns Hopkins University. The seven-day average of daily new cases is over 480,000.
    The dramatic rise in caseloads, fueled by the highly contagious omicron and delta virus strains, is causing worker shortages and disrupting businesses. The Centers for Disease Control and Prevention recently shortened the Covid isolation period to five days for people without symptoms, down from 10 days.

    Individuals who test positive for Covid-19 and stay home to recover and isolate from others aren’t eligible for jobless benefits, according to Michele Evermore, a senior policy advisor for unemployment insurance at the U.S. Department of Labor.
    Unemployment benefits are a type of social insurance paid on a weekly basis. The law requires Americans to be “able and available” for work to qualify for the assistance.

    An individual who has Covid-19 doesn’t meet this core requirement, Evermore said.

    “[Unemployment insurance] is not intended to be used as paid sick leave,” the Labor Department wrote to state workforce agencies, which administer benefits, in March 2020.

    Not always the case

    This wasn’t always the case during the pandemic. The CARES Act relief law created a temporary unemployment program offering jobless aid to sick individuals and others (like gig workers) who typically don’t qualify for unemployment insurance.
    The federal program, Pandemic Unemployment Assistance, expired on Labor Day. (Many Republican-led states opted out of the program early, in June or July.)
    More from Personal Finance:Elizabeth Holmes verdict offers lessons for investorsWhen auto insurance is most and least expensiveWhen it makes sense to sell stocks
    While those who test positive for Covid-19 no longer qualify for jobless benefits, that’s not necessarily true of people who isolate due to a potential Covid exposure and must miss work, Evermore said.
    They may be eligible because they’re technically able and available to work, she said.
    For example: Someone with an outdoor job (perhaps a lumberjack or construction worker) who must quarantine due to potential Covid exposure can technically do a few weeks of online work while they isolate. They can work, just not their customary job.

    “An individual may be quarantined or otherwise affected by Covid-19 but still eligible for [unemployment compensation], depending on state law,” according to the Labor Department memo.
    Americans with Covid-19 may get paid sick leave through their workplace, in which case they wouldn’t need unemployment benefits.
    However, temporary federal laws that increased the availability of paid leave earlier in the pandemic have expired. (One required certain businesses to offer paid sick leave, but expired at the end of 2020; another offered tax credits to employers to reimburse them for the cost of offering leave, but expired Sept. 30.)

    WATCH LIVEWATCH IN THE APP More

  • in

    Why Biogen's Alzheimer's drug Aduhelm is so controversial

    Despite high expectations, Biogen has reported only a fraction of estimated sales for its historic Alzheimer’s treatment.
    The FDA approved Aduhelm in June as the first Alzheimer’s drug to try and thwart cognitive decline.
    The company now plans to slash Aduhelm’s controversial list price by roughly half in a bid to boost sales.

    The U.S. Food and Drug Administration’s approval of Biogen’s Alzheimer’s drug Aduhelm in June was heralded as a historic triumph in the fight against a disease that kills thousands of Americans every year.
    But the excitement around the first FDA-approved drug to target the underlying cause of the memory-robbing disease—not just its symptoms—has ebbed since then. The drugmaker reported just $300,000 in revenue from Aduhelm sales during the third quarter, a fraction of what Wall Street was expecting.

    Physicians have been split over whether clinical trial data proves the monoclonal antibody actually slows cognitive decline. What’s more, Medicare is debating whether to cover seniors on the government-run insurance program for Alzheimer’s treatments, a decision that is crucial to their profit potential.
    The Centers for Medicare and Medicaid Services plans to issue a draft decision by mid-January, a spokesperson told CNBC.
    Meanwhile, shares of the Cambridge, Massachusetts-based biotech have cratered roughly 40% since the beginning of June. Given Aduhelm’s lackluster debut, as well as generic competition for Biogen’s other drugs, the company now plans to cut $500 million in annual costs.
    In December, it also said it would slash Aduhelm’s controversial $56,000 annual list price by about 50% in a bid to boost sales. The company anticipates 50,000 new patients could start Aduhelm in 2022 with insurance coverage and greater access to diagnostics and specialized centers.
    “In terms of this new drug, we are keeping an open mind,” said Dick Novik, who retired from the broadcast business to help care for his wife, Eugenia Zukerman, following her Alzheimer’s diagnosis.

    “If only there were a way of being more certain in our minds that it works,” Novik told CNBC.
    Why is Biogen’s Alzheimer’s drug so controversial? Watch the video above to learn.

    WATCH LIVEWATCH IN THE APP More

  • in

    Auto insurance is expected to cost 5% more in 2022. Here's where it's the most and least expensive

    The most expensive state for car insurance is Michigan, with an average annual premium of $2,858.
    Drivers in Hawaii pay the least on average, at $824 a year.
    There are a variety of ways you can reduce what you pay to insure your car.

    Prostock-Studio | iStock | Getty Images

    Like many things right now, the cost of auto insurance is rising.
    For 2022, the average national cost to insure a car is expected to jump 5% to $1,707 annually, up from $1,663 in 2021, according to Insurify.

    “Our prediction for 2022 is on par with projected inflation rates, and factors in the continued elevation in reckless driving behaviors, which have become more frequent following the 2020 Covid lockdowns,” said Tanveen Vohra, Insurance Specialist at Insurify.
    More from Personal Finance:10 things that will be more expensive in 2022Here’s why your tax refund could be smaller4 ways to lower your grocery bill as prices soar
    Inflation is touching most aspects of American life, with everything from groceries to cars and gas jumping in cost. The latest data shows inflation rising at an annual 6.8% clip, far above the Federal Reserve’s 2% target.
    Meanwhile, Americans drove 32% more miles in March, April and May of 2021 compared with the same months in 2020, when shutdowns early in the pandemic resulted in fewer cars on the road, according to Insurify’s research.
    However, the fatality rate was 26% higher in spring 2021 than it was in 2019, pre-pandemic, “suggesting that reckless driving habits adopted during initial pandemic shelter-in-place orders have endured well beyond the onset of the pandemic,” the report says.

    Of course, the exact amount you pay is based on a variety of factors, including your car’s make and model, your coverage choices, as well as things like your driving record and, sometimes, even your credit score.
    Location also matters. The most expensive state for car insurance is Michigan, at an average of $2,858 a year, followed by New York and Rhode Island, both averaging $2,321 annually, according to Insurify.
    The least expensive state is Hawaii, with an average yearly layout of $824. North Carolina ($924) and Maine and Vermont (both average $945) are right behind that.
    Additionally, if you live in an urban area, you’ll pay more on average ($1,666 yearly) compared with drivers in rural spots ($1,472 a year). Also, a single prior traffic offense can push your premiums up by an average of 35%, the research shows.

    There are ways to reduce what you pay, beyond dropping parts of your coverage or increasing your deductibles.
    For instance, bundling — i.e., getting both auto and homeowners insurance from the same provider — can save you an average of 8% yearly, according to Insurify. Or, if you are a member of the military, you could save 2.2%. And if you take a driver safety training course as an older American, you could save as much as 15.2%.
    “The best way to find a lower rate, however, is to shop around and get quotes from multiple insurers to find the one that gives you the best deal,” Vohra said.
    Insurify analyzed more than 40 million auto insurance premiums in its database to produce its research.

    WATCH LIVEWATCH IN THE APP More

  • in

    New Zealand Covid experts take legal action against employer over harassment from public

    Shaun Hendy and Siouxsie Wiles had filed separate claims with the Employment Relations Authority, against the vice chancellor of the University of Auckland.
    They claimed that their employer had “responded inadequately or not at all to their health and safety concerns” amid harassment from members of the public.
    According to a ruling dated Dec. 24, the Employment Relations Authority approved the pair’s requests to move their claims up to New Zealand’s Employment Court.

    University of Auckland physics professor Shaun Hendy, whose work on Covid-19 scenario modelling has helped inform the New Zealand government’s response to the pandemic.
    Phil Walter | Getty Images

    Two of New Zealand’s top Covid-19 experts are taking legal action against their employer, the University of Auckland, over its response to the harassment the scientists have faced from the public amid the pandemic.
    Shaun Hendy, a physics professor, and Siouxsie Wiles, an associate professor of medical science, filed separate claims with the Employment Relations Authority, against the vice chancellor of the University of Auckland.

    Hendy and Wiles claimed their employer had “responded inadequately or not at all to their health and safety concerns” amid harassment from members of the public who “disliked or disapproved” of their commentary on the coronavirus.
    According to a ruling dated Dec. 24, the Employment Relations Authority approved the pair’s requests to move their claims up to New Zealand’s Employment Court.
    The ruling stated that Hendy and Wiles had “suffered vitriolic, unpleasant, and deeply personalised threats and harassment that has had a detrimental impact” on their physical safety and mental health. It also said the harassment they faced has not only continued but has been “getting worse and ‘more extreme’ in nature.”
    Hendy’s work on Covid-19 scenario modeling has helped inform the New Zealand government’s response to the pandemic. Meanwhile, Wiles was named the ‘New Zealander of the Year’ in 2021 for her prominent role in explaining the science of the coronavirus pandemic to the public and media.
    The scientists said they are “expected” to provide public commentary as part of their employment. However, this is something that the vice chancellor denied, though acknowledged that they are “entitled to do so.”

    Hendy and Wiles started raising concerns about the harassment in April 2020. According to the ruling, they had suffered harassment via email, on social media and video sharing platforms, as well as in the form of in-person confrontations and threats of physical confrontations.
    For example, the ruling detailed how Wiles had been the victim of “doxing,” where someone’s personal information is shared online. She had also received an “associated threat to physically confront her at her home.”
    In addition, Hendy was physically confronted in his office on the university campus by someone who threatened to “see him soon.”
    According to the ruling, Hendy, Wiles and another colleague were urged in a letter from the vice chancellor in August to keep their public commentary to a minimum. The letter also suggested that they take paid leave to enable them “to minimize any social media comments at present.”
    However, the vice chancellor denies instructing the scientists to minimize their public commentary, claiming it “merely advised the applicants that doing so is an option they may want to consider.”
    Hendy and Wiles aren’t the only Covid experts to have been the subject of harassment amid the pandemic.
    Chief White House medical advisor Dr. Anthony Fauci has talked about receiving death threats, which have required him to be protected by federal agents.

    WATCH LIVEWATCH IN THE APP More

  • in

    U.S. reports over 1 million new daily Covid cases as omicron surges

    The U.S. reported a record number of new Covid cases on Monday, with over 1 million new infections.
    A total of 1,082,549 new coronavirus cases were reported Monday, according to data from Johns Hopkins University, as the highly infectious omicron variant continues to spread throughout the country and beyond.
    The U.S. also has the highest seven-day average of new cases in the world, according to Johns Hopkins rankings.

    US Army Critical Care Nurse, Captain Edward Rauch Jr. (L), turns a Covid-19 patient on a ventilator at Beaumont Hospital in Dearborn, Michigan on December, 17, 2021.
    Jeff Kowalsky | AFP | Getty Images

    The U.S. has reported a record single-day number of daily Covid cases, with more than 1 million new infections.
    A total of 1,082,549 new coronavirus cases were reported Monday, according to data compiled by Johns Hopkins University, as the highly infectious omicron variant continues to spread throughout the country.

    The new daily tally brings the total number of cases confirmed in the U.S. since the start of the pandemic to 56,189,547. In total, the virus has caused 827,748 deaths across the country.
    The record single-day total may be due in part to delayed reporting from over the holiday weekend. A number of U.S. states did not report data on Dec. 31, New Year’s Eve, and many do not report data on weekends, meaning that some of these cases could be from positive tests taken on prior days.
    Nonetheless, as of Jan. 3, the seven-day average of daily new U.S. cases is 480,273, meaning the U.S. has the highest 7-day average of new cases in the world, according to JHU’s rankings.
    About 98,000 Americans are hospitalized with Covid-19, according to a seven-day average of data from the Department of Health and Human Services as of Jan. 3, up 32% from a week ago. That figure is approaching peak delta wave levels when about 103,000 people were in hospital beds with Covid across the country in early September, but remains lower than last winter’s high mark of roughly 137,000 U.S. hospitalizations.
    The U.S. is reporting an average of about 1,200 daily Covid deaths for the week ending Jan. 3, Hopkins data shows, well below the record numbers seen following last year’s holiday season when the daily average held above 3,000 for about a month starting in January 2021. The death toll tends to lag rises in case counts and hospitalizations, however.

    In recent weeks, the U.S. has seen the omicron variant starting to edge out the previously dominant delta strain of the virus.
    The latest available weekly data from the U.S. CDC, ending on Dec.25, estimates that the delta variant accounted for around 41% of cases while omicron made up around 58.6% of U.S. infections.
    U.S. health officials have urged Americans to get vaccinated and boosted against the coronavirus given concerns over the new variant.
    Early studies suggested that Covid vaccines are less effective against the omicron variant compared with the delta strain and other variants. But the same studies have indicated that three vaccine doses — the two preliminary shots plus a booster — significantly increase the level of protection against omicron.
    Research has also suggested that the omicron variant causes less severe infections.
    The rise of the variant led to thousands of flight cancellations during the holiday season and has led some businesses and schools to consider temporary closures. Several major Wall Street banks have asked employees to work from home for the first few weeks of January.
    — CNBC’s Nate Rattner contributed reporting to this story.

    WATCH LIVEWATCH IN THE APP More

  • in

    Stocks making the biggest moves in the premarket: Foot Locker, Under Armour, Warner Music and more

    Take a look at some of the biggest movers in the premarket:
    Foot Locker (FL) – The athletic footwear and apparel retailer dropped 3.9% in the premarket after J.P. Morgan Securities downgraded it to “underweight” from “neutral,” pointing to cost pressures and tougher competition.

    Under Armour (UAA) – Under Armour rose 2.5% in premarket trading after a Baird upgrade to “outperform” from “neutral.” Baird said the athletic apparel maker’s stock would benefit from a cyclical recovery in earnings.
    Warner Music (WMG) – Warner Music slid 4% in premarket action following news of an 8.6 million share sale by affiliates of stakeholder Access Industries. Warner Music will not receive any proceeds from the sale.
    Apple (AAPL) – Apple remains on watch after becoming the first U.S. company to exceed $3 trillion in market value, reaching that milestone on Monday before pulling back. Apple straddled the $3 trillion price of $182.86 per share during premarket trading.
    Ford Motor (F) – Ford will start accepting purchase orders this week for its F-150 Lightning electric pickup truck. It had previously shut down its reservation system for the truck due to an overwhelming response. Ford added 1.4% in the premarket.
    Coca-Cola (KO) – The beverage giant’s stock rose 1% in the premarket after Guggenheim upgraded the stock to “buy” from “neutral,” citing a number of factors including strong emerging market performance and a faster-than-expected recovery in on-premises sales.

    Hewlett Packard Enterprise (HPE) – Hewlett Packard Enterprise was upgraded to “overweight” from “equal weight” at Barclays, which points to a number of factors including an attractive valuation for the enterprise technology company. Hewlett Packard Enterprise gained 2.3% in the premarket.
    Toyota Motor (TM) – Toyota plans to launch its own automotive operating system by 2025, according to a report by Japan’s Nikkei news service. The system would be able to handle advanced operations such as autonomous driving. Toyota rose 2.5% in premarket action, with shares benefiting as the dollar rose to a nearly five-year high against the Japanese yen.
    General Electric (GE) – GE gained 1.4% in premarket trading after it was upgraded to “outperform” from “neutral” at Credit Suisse, with a price target of $122. Credit Suisse said a recent sell-off in GE shares gives investors the opportunity to benefit from a cyclical aerospace industry recovery.
    BlackBerry (BB) – A judge ruled against BlackBerry’s bid to have a more than eight-year-old investor lawsuit thrown out. The suit claims BlackBerry – which no longer makes smartphones and now focuses on cybersecurity software – inflated the success and profitability of its BlackBerry 10 smartphone. The class-action suit could go to trial later this year.
    Blackbaud (BLKB) – The cloud software provider announced a deal to acquire social impact technology company EVERFI in a deal worth $750 million in cash and stock. Blackbaud expects the acquisition to be immediately accretive to its earnings.

    WATCH LIVEWATCH IN THE APP More

  • in

    India reports the highest number of daily Covid cases since early September

    There were 37,379 new cases reported over a 24-hour period, government data showed Tuesday.
    That was the highest reported figure since September and marked a sharp jump from the 6,358 cases reported a week earlier on Dec. 28.
    Maharashtra and Delhi together account for around half of all cases in India attributed to the omicron variant.

    A health worker administers a dose of the Bharat Biotech Ltd. Covaxin vaccine at a Covid-19 vaccination center set up at the Delhi Municipal Corp. Public Health Center in the Daryagunj area of New Delhi, India, on Monday, June 21, 2021.
    Sumit Dayal | Bloomberg | Getty Images

    India’s Covid-19 cases are rising again as several states grapple with a growing number of infections attributed to the omicron variant.
    There were 37,379 new cases reported over a 24-hour period, government data showed Tuesday. That was the highest reported figure since September and marked a sharp jump from the 6,358 cases reported a week earlier on Dec. 28.

    The state of Maharashtra, which is home to India’s financial hub Mumbai, has so far detected 568 cases of the omicron variant while the capital territory of Delhi reported 382 cases. Together, they account for around half of all cases in India attributed to the new heavily mutated strain.
    Delhi Chief Minister Arvind Kejriwal tweeted on Tuesday that he tested positive for Covid and was experiencing “mild symptoms.” He said he was self-isolating at home and urged close contacts to do the same and get tested.
    Omicron was first identified by South African scientists in November. The variant has rapidly spread around the globe, with places like the United States and the United Kingdom reporting massive surges.

    CNBC Health & Science

    WATCH LIVEWATCH IN THE APP More

  • in

    China Evergrande shares reopen higher; developer says contracted sales dropped 38.7% in 2021

    A filing Tuesday showed Evergrande’s contracted sales of properties totaled 443.02 billion yuan ($69.22 billion) last year, down 38.7% from the 723.25 billion yuan in contracted sales reported for 2020.
    The figures show how demand is drying up for the developer’s main line of business.
    Evergrande shares reopened higher in Hong Kong on Tuesday afternoon, after trading was halted Monday morning.

    An exterior view of China Evergrande Centre in Hong Kong, China March 26, 2018.
    Bobby Yip | Reuters

    BEIJING — Indebted property developer China Evergrande’s contracted sales plunged last year as the real estate giant struggled to repay creditors.
    A filing Tuesday showed the company’s contracted sales of properties totaled 443.02 billion yuan ($69.22 billion) last year, down 38.7% from the 723.25 billion yuan in contracted sales reported for 2020.

    Evergrande shares reopened higher in Hong Kong on Tuesday afternoon, with shares trying to hold gains of about 3%.
    Trading was halted as of 9 a.m. Monday, with shares at 1.59 Hong Kong dollars (20 cents) each. That’s just above the all-time intraday low of 1.42 Hong Kong dollars per share set on Dec. 24, according to FactSet.
    Shares have plunged more than 88% over the last 250 trading days. The company missed payments to creditors in December, Fitch Ratings said, sending the developer into default.
    Evergrande, China’s second-biggest developer by sales in 2020, is the largest Chinese real estate developer by issuance of offshore, U.S. dollar-denominated debt, which stood at $19 billion last year. The developer had a total of $300 billion in liabilities as of last year.

    The company said Tuesday it “will continue to actively maintain communication with creditors, strive to resolve risks and safeguard the legitimate rights and interests of all parties.”

    The developer added that a demolition order for its Ocean Flower Island project only applied to 39 buildings, according to Tuesday’s filing with the Hong Kong stock exchange.
    Evergrande’s public statements have tried to assure investors the company is completing and delivering apartments to customers. But demand is drying up for the developer’s future projects.
    The full-year figures indicate contracted sales of only 720 million yuan in just over two months, between Oct. 21 and Dec. 31. In contrast, contracted sales in August totaled 38.08 billion yuan, and stood at 3.65 billion yuan between the beginning of Sept. and Oct. 20.
    S&P Global Ratings warned in November that an Evergrande default “is highly likely” since the company is no longer able to sell new homes. Like other Chinese real estate developers, Evergrande’s business model relies heavily on sales of apartments to customers before the units are completed.

    Read more about China from CNBC Pro

    Evergrande’s troubles have raised concerns about the health of China’s massive real estate industry overall.
    Chinese authorities have called the company a “unique case.” Analysts have pointed out that in contrast with other developers, Evergrande made little progress toward complying with new regulations aimed at restricting the industry’s reliance on debt.
    However, a prominent Chinese developer that met government requirements on debt, has also warned of falling sales.
    Shanghai Shimao told investors in late December it would be difficult to hit its full-year contracted sales target of 38 billion yuan since sales in the first 11 months of the year were 28.2 billion yuan, according to a filing. In addition to stock declines, the company’s bonds have plunged in the last few months.

    WATCH LIVEWATCH IN THE APP More